Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients – A Dual-Center Retrospective Cohort Study

Journal of Blood Medicine

关键词: leukemia;    hyperleukocytosis;    leukostasis;    leukapheresis;    chemotherapy;    survival;   

DOI  :  

来源: DOAJ

【 摘 要 】

Ikhwan Rinaldi,1 Resti Mulya Sari,2 Vanya Utami Tedhy,3 Kevin Winston3 1Division of Hematology and Medical Oncology, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 2Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 3Faculty of Medicine, Universitas Indonesia, Jakarta, IndonesiaCorrespondence: Ikhwan RinaldiDivision of Hematology and Medical Oncology, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, IndonesiaTel [phone]Email [e-mail]: Leukostasis is a medical emergency with high mortality which often occurs in acute myeloid leukemia patients with hyperleukocytosis. One of the therapies that can be used for leukostasis in acute myeloid leukemia is leukapheresis. However, whether leukapheresis can provide better survival benefit when compared with patients not receiving leukapheresis is still unclear. Hence, we aimed to evaluate the effect of chemotherapy plus leukapheresis combination versus chemotherapy only on 28-day survival of acute myeloid leukemia patients with leukostasis.Methods: This study was a dual-center retrospective cohort using secondary data from medical records collected from November 2018 to March 2019. Inclusion criteria were adult patients aged 18 years old or above, diagnosed with acute leukemia with hyperleukocytosis status defined by WBC count greater than 100,000/uL, and with symptoms of leukostasis. One-month survival analysis was conducted using Kaplan–Meier curve method. Univariate and multivariate analyses were then conducted using Cox proportional hazards model to obtain value of hazard ratio (HR) with a 95% confidence interval (CI).Results: A total of 38 patients were obtained for analysis. The median overall survival was 25 days (95% CI: 17.001– 32.999 days) in the chemotherapy only group and 20 days (95% CI: 1.497– 38.503) in the chemotherapy with leukapheresis group. The use of leukapheresis did not affect 28-day survival (HR: 1.140; 95% CI: 0.396– 3.283; p value: 0.809) and 7-day survival (HR: 1.073; 95% CI: 0.277– 4.152; p value: 0.919). In the multivariate analysis, age ≥ 60 years, blast percentage ≥ 90%, creatinine ≥ 1.4 mg/dL, and presence of disseminated intravascular coagulation were associated with worse 28-day survival.Conclusion: AML patients with leukostasis who received both chemotherapy and leukapheresis did not have better 28-day survival and 7-day survival when compared with patients receiving chemotherapy only. Old age, high blast percentage, high creatinine, and presence of disseminated intravascular coagulation were prognostic factors for worse 28-day survival.Keywords: leukemia, hyperleukocytosis, leukostasis, leukapheresis, chemotherapy, survival

【 授权许可】

Unknown